Patents by Inventor Robert Paul Hof

Robert Paul Hof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of S1P Receptor Agonists in Heart Diseases
    Publication number: 20110136739
    Abstract: The invention relates to the use of sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 9, 2011
    Inventors: Volker BRINKMANN, Gilles FEUTREN, Robert Paul HOF
  • Use of S1P receptor agonists in heart diseases
    Patent number: 7910626
    Abstract: The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: March 22, 2011
    Assignee: Novartis AG
    Inventors: Volker Brinkmann, Gilles Feutren, Robert Paul Hof
  • Use of S1P receptor agonists in heart diseases
    Publication number: 20090029922
    Abstract: The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.
    Type: Application
    Filed: October 2, 2008
    Publication date: January 29, 2009
    Inventors: Volker Brinkmann, Gilles Feutren, Robert Paul Hof
  • New use for 1,3-propanediol derivatives
    Publication number: 20030069315
    Abstract: Use of a compound of formula I 1
    Type: Application
    Filed: September 30, 2002
    Publication date: April 10, 2003
    Inventors: Sylvain Cottens, Robert Paul Hof, Roland Wenger
  • Use for 1,3-propanediol derivatives
    Patent number: 6486209
    Abstract: Use of a compound of formula I wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: November 26, 2002
    Assignee: Novartis AG
    Inventors: Sylvain Cottens, Robert Paul Hof, Roland Wenger
  • Use for 1,3-propanediol derivatives
    Patent number: 6274629
    Abstract: Use of a compound of formula (I) wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: August 14, 2001
    Assignee: Novartis AG
    Inventors: Sylvain Cottens, Robert Paul Hof, Roland Wenger